US20180271786A1 - Enema for rectal application - Google Patents

Enema for rectal application Download PDF

Info

Publication number
US20180271786A1
US20180271786A1 US15/546,476 US201515546476A US2018271786A1 US 20180271786 A1 US20180271786 A1 US 20180271786A1 US 201515546476 A US201515546476 A US 201515546476A US 2018271786 A1 US2018271786 A1 US 2018271786A1
Authority
US
United States
Prior art keywords
enema
rectal application
budesonide
day
rectal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/546,476
Other languages
English (en)
Inventor
Yoji Yamada
Syoji KONDO
Toshifumi KAJIOKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Falk Pharma GmbH
Original Assignee
Dr Falk Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma GmbH filed Critical Dr Falk Pharma GmbH
Assigned to DR. FALK PHARMA GMBH reassignment DR. FALK PHARMA GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EA PHARMA CO., LTD.
Assigned to EA PHARMA CO., LTD. reassignment EA PHARMA CO., LTD. CONFIRMATORY Assignors: AJINOMOTO CO., INC.
Assigned to AJINOMOTO CO., INC. reassignment AJINOMOTO CO., INC. CONFIRMATORY Assignors: KAJIOKA, TOSHIFUMI, KONDO, SYOJI, YAMADA, YOJI
Publication of US20180271786A1 publication Critical patent/US20180271786A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • the present invention relates to an enema for rectal application containing budesonide as an active ingredient in order to treat an inflammatory bowel disease, or to prevent a relapse.
  • Ulcerative colitis is a nonspecific inflammatory bowel disease of unknown cause that can cause ulcer and erosion mainly in a large intestine mucosa
  • Crohn's disease is an inflammatory bowel disease of unknown cause which causes a discontinuous chronic granulomatous inflammation mainly in an entire digestive tract from an oral cavity to an anus.
  • bloody stool, mucous and bloody stool, diarrhea, abdominal pain, and the like are common symptoms, and when the symptoms become severe, general social life is interfered.
  • curative treatment is not established for these, and thus once these develop, these will repeat relapse and remission. Therefore, in order to improve the quality of life (QOL) of patients, it is important to maintain the remission period as long as possible.
  • medication treatment is done for the purpose of leading to clinical remission. Therefore, for example, in ulcerative colitis, in a case where the clinical symptoms disappear or are improved to the extent that the symptoms do not interfere with daily life, such as bloody stools disappear and a defecation frequency decreases to the extent that the defecation does not interfere with the daily life, even in a case where mucosal inflammation of the intestinal tract is not completely disappeared and mild inflammation is confirmed, it is said to be remission.
  • Budesonide (+)-[(RS)-16 ⁇ ,17 ⁇ -Butylidenedioxy-11 ⁇ ,21-dihydroxy-1,4-pregnadiene-3,20-dione]) is a steroid drug applied as a therapeutic agent for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
  • Budesonide is effective for topical administration and is generally used as an enema for rectal application for pharmaceutical foams packed with compressed gas and enema agents (refer to PTL 1).
  • 2 mg of budesonide is administered once a day for 6 weeks.
  • An object of the present invention is to provide an enema for rectal application in which the mucosal curing effect is significantly superior to an enema of the related art, in an enema for rectal application containing budesonide as an active ingredient in order to treat an inflammatory bowel disease, or to prevent a relapse.
  • the present inventors find that the mucosal curing effect is significantly higher as compared with the case of administration once a day for 6 weeks in the related art, by administering an enema for rectal application with budesonide as an active ingredient twice a day for 6 weeks, and thus completes the present invention.
  • an embodiment of the present invention relates to an enema for rectal application of the following [1] to [6].
  • a package of an enema for rectal application in which the enema for rectal application according to any one of the above [1] to [4] containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times.
  • a manufacturing method of a package of an enema for rectal application in which the enema for rectal application according to any one of the above [1] to [4] is adjusted such that the enema for rectal application containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times.
  • [1A] For a subject with inflammatory bowel disease or a subject after improvement of symptoms of inflammatory bowel disease, a method for a treatment or prevention of relapse of inflammatory bowel disease by transanally administrating a dose of 1.5 to 2.5 mg of budesonide twice a day for 6 weeks.
  • [2A] The method for the treatment or prevention of relapse of inflammatory bowel disease according to the above [1A] by administrating 2.0 mg of budesonide per dose.
  • [3A] The method for the treatment or prevention of relapse of inflammatory bowel disease according to the above [1A] to [2A], in which the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
  • [4A] The method for the treatment or prevention of relapse of inflammatory bowel disease according to the above [1A] to [3A], in which in the administration, the enema for rectal application containing the budesonide is taken.
  • [5A] The method for the treatment or prevention of relapse of inflammatory bowel disease according to the above [4A], in which the enema for rectal application has a foamy shape or a liquid shape.
  • [6A] The method for the treatment or prevention of relapse of inflammatory bowel disease according to the above [1A] to [5A], in which the administration of twice a day is performed with an interval of at least 6 hours between the first and second administrations.
  • [1B] A composition for the treatment or prevention of relapse of inflammatory bowel disease containing 1.5 to 2.5 mg of budesonide.
  • [2B] The composition for the treatment or prevention of relapse of inflammatory bowel disease according to the above [1B] containing 2.0 mg of budesonide.
  • [3B] A package of the composition for the treatment or prevention of relapse of inflammatory bowel disease, the package containing an enema foaming agent that can be administered 14 times in a fixed dose of the composition for the treatment or prevention of relapse of inflammatory bowel disease according to the above [1B] or [2B].
  • [1C] Use of the composition for the treatment or prevention of relapse of inflammatory bowel disease according to the above [1B] or [2B] in the manufacture of the enema for rectal application.
  • the enema for rectal application according to the present invention has remarkably high curing effect on intestinal mucosa where ulcer and erosion occur due to inflammation. Therefore, the enema for rectal application according to the present invention is extremely excellent as an enema for rectal application in order to treat inflammatory bowel disease such as ulcerative colitis and Crohn's disease or the like, or to prevent a relapse.
  • FIG. 1 is a diagram illustrating mucosal remission rates (%) of each group in Application Example 1.
  • FIG. 2 is a diagram illustrating mucosal curing rates (%) of each group in Application Example 1.
  • An enema for rectal application according to the present embodiment is administered (taken) with budesonide as an active ingredient, and 1.5 to 2.5 mg of budesonide twice a day for 6 weeks in order to treat an inflammatory bowel disease, or to prevent a relapse.
  • budesonide is used as a therapeutic agent for the inflammatory bowel disease by administering 2 mg once a day for 6 weeks directly to a rectum.
  • a dose and administration period per dose of the enema for rectal application according to the present embodiment are the same as those of the method of the related art, the effect of curing an inflammation of an intestinal mucosa is significantly superior to the case of taking once a day in the related art.
  • the dose per day of the enema for rectal application according to the present embodiment is twice as much as that of the method of the related art, the enema can be safely taken as much as the method of the related art without any special side effects as compared with the method of the related art.
  • the enema for rectal application described above is administered twice a day until two weeks, but in the present embodiment, the enema can be administered twice a day over two weeks. Furthermore, in order to obtain a sufficient effect, it is preferable to take twice a day for 6 weeks. That is, the administration period can be selected from more than 2 weeks and not more than 6 weeks, and is preferably 6 weeks.
  • the week means an approximate period, and even if the administration period increases or decreases for several days due to convenience of administration to a subject, the effect can be obtained, so that the administration period includes approximately ⁇ 3 days as a guide.
  • a method of transanal administration by suppository or the like is included.
  • Budesonide has two diastereomers of 22R and 22S.
  • the active ingredient of the enema for rectal application according to the present embodiment may be any one of these diastereomers or may be a mixture thereof (for example, a racemate containing approximately equal amounts of both diastereomers).
  • 22R of the two diastereomers of budesonide is more active than 22S, as the active ingredient of the enema for rectal application according to the embodiment, it is preferable to use racemic or 22 R diastereomer, and more preferably 22R diastereomer.
  • the enema for rectal application according to the present embodiment is taken twice a day, and the time point of taking the dose within one day is not particularly limited, it is preferable to have an interval at least 6 hours or more and less than one day (24 hours), and more preferable to take in the morning and night. In addition, as much as possible, it is preferable to take after defecation.
  • budesonide twice a day in adults within the range of 1.5 to 2.5 mg per dose, and particularly preferable to take budesonide twice a day so as to be 2 mg per dose.
  • the pH of the liquid agent is preferably 6.0 or less, more preferably 3.0 to 6.0 from the viewpoint of physiological tolerability, and still more preferably 3.5 to 6.0.
  • solvent for dissolving budesonide is preferably an alcohol or a mixed solvent of water and alcohol.
  • the alcohols include propylene glycol, ethanol, isopropanol, and the like.
  • the alcohol used as the solvent may be only one type, or two types or more of alcohols may be used in mixture.
  • the ratio of alcohols to water is preferably 100:0 to 80:20, more preferably 98:2 to 93:7, in the mass ratio of water:alcohol.
  • the enema for rectal application according to the present embodiment preferably contains EDTA sodium salt (sodium ethylenediaminetetraacetate) and/or cyclodextrins.
  • EDTA sodium salt sodium ethylenediaminetetraacetate
  • cyclodextrins ⁇ -cyclodextrin, hydroxy- ⁇ -cyclodextrin, or ⁇ -cyclodextrin is preferable.
  • the enema for rectal application according to the embodiment may contain various pharmaceutically acceptable additives according to the requirements of the preparation.
  • additives include pH adjusters, preservatives, thickeners, emulsifiers, and the like.
  • pH adjuster include acids such as acetic acid, citric acid, tartaric acid, hydrochloric acid, phosphoric acid and the like; bases such as potassium hydroxide or sodium hydroxide; or a buffer solution such as a hydrochloric acid buffer solution, a phthalate buffer solution, a phosphate buffer solution, a borate buffer solution, an acetate buffer solution or a citrate buffer solution, and the like.
  • preservatives examples include ethanol, chlorobutanol, benzyl alcohol, phenylethanol, sorbic acid, benzoic acid, sodium disulfite, p-hydroxybenzoate, phenol, m-cresol, p-chloro-m-cresol, a quaternary ammonium salt, or a chlorhexidine, and the like.
  • the thickener examples include gelatin, tragacanth, pectin, cellulose derivatives (for example, methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose sodium, and the like), polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acids, xanthan gum, or xanthan gum, and the like.
  • emulsifier examples include aliphatic alcohols such as cetearyl alcohol, cetyl alcohol, stearyl alcohol or myristyl alcohol; and polyoxyethylene alkyl ethers such as polyoxyethylene cetostearyl ether or polyoxyethylene lauryl ether, and the like.
  • the dosage form of the enema for rectal application according to the present embodiment is not particularly limited as long as the enema is transanally administered directly into the intestinal tract.
  • the enema for rectal application in the form of a foamy shape or a liquid shape can be used, and examples thereof include a rectal foaming agent, an enema agent, a suppository, and the like.
  • the enema agent may be one that can be distributed as a liquid agent or may be prepared by dissolving a tablet containing budesonide in a solvent such as water just before taking.
  • a rectal foaming agent or an enema agent is preferable, and the rectal foaming agent is particularly preferable, since the enema can be directly administered into the large intestine from the anus.
  • the foaming agent refers to a mode in which bubbles are formed by an aqueous solution of the liquid agent to form the foams of aggregated bubbles, and the like. The foaming agent is administered by spraying the foam on the subject or the like.
  • the rectal foaming agent, the enema agent, and the suppositorie containing budesonide as the active ingredient can be prepared by a known method of the related art, except that these are manufactured so that the dose of budesonide is 1.5 to 2.5 mg per dose.
  • Compositions for the treatment or the prevention of relapse of inflammatory bowel disease containing budesonide and the other ingredients described above can be adjusted to the form of the various enemas for rectal application described above.
  • the rectal foaming agent and the enema agent containing budesonide as the active ingredient can be manufactured by the method described in PTL 1.
  • the rectal foaming agent containing budesonide as the active ingredient can be manufactured as follows.
  • Budesonide dissolved in alcohol is added to the solution prepared by dissolving a preservative or an emulsifier necessary for foam formation in a mixed solvent of alcohols or water and alcohols, and mixed. Thereafter, an aqueous solution in which EDTA sodium salt and an acid are dissolved is stirred while homogenizing.
  • the obtained solution is sealed in a gas filling pack equipped with a commercial valve system as a device for single or multiple administrations, and subsequently propellant gas is added.
  • the propellant gas hydrocarbons such as isobutane, n-butane or propane/n-butane mixture are preferable.
  • the gas filling pack may further be provided with a plastic applicator chip.
  • the enema for rectal application according to the present embodiment may be provided for each medicine package of a single dose, but it may be provided by appropriately adjusting the form that is easy to administer twice a day for 6 weeks.
  • an enema foaming agent can be provided by packing a foaming agent of 14 times (for one week) in aluminum cans, or packaging the foaming agent for 2 weeks (for 28 times) in aluminum cans (aerosol). In addition, these may be combined for 2 to 6 weeks.
  • Such packages are easy to appropriately use for prescription for one person.
  • the enema for rectal application according to the embodiment is excellent in the curing effect of the intestinal mucosa, it is preferably used in order to treat inflammatory bowel disease, or to prevent a relapse.
  • the treatment in the embodiment widely refers to improvement of the subject's symptoms.
  • the prevention of relapse in the embodiment widely refers to prevent symptom deterioration (relapse) of the symptoms of the disease completely or to some extent for the subject after improvement. Since inflammation of the mucosa can be further improved by taking the enema for rectal application according to the embodiment than the method of the related art of taking budesonide once a day, it can be expected that patients taking the enema for rectal application according to the embodiment can maintain remission for a longer period of time after taking.
  • the enema for rectal application according to the embodiment may be taken in order to treat pouchitis which is an inflammation occurring in the ileac pouch (formed in a pouch shape) after total colonic removal of ulcerative colitis, or to prevent a relapse, similarly to budesonide enema of the related art for rectal application (Gionchetti et al., Alimentary Pharmacology & Therapeutics, 2007, vol. 25, p. 1231-1236; Sambuelli et al., Alimentary Pharmacology & Therapeutics, 2002, vol. 16, p. 2′7-34).
  • Dose responsiveness, efficacy and safety are investigated for patients with active ulcerative colitis when budesonide 2 mg is rectally administered once a day or twice a day for 6 weeks by a double-blind comparative study with placebo as a control (clinical trial number: Japic CTI—132294).
  • an aerosol with fixed dose injection type for rectal injection (rectal foaming agent) is used as a test drug, in which 25 mL (1.35 g) of white creamy foam containing 2 mg of budesonide is released by one injection.
  • the aerosol for rectal injection is approved in Europe at a dosage and dose of budesonide 2 mg once a day (trade name: Budenofalk 2 mg/dose rectal foam, manufactured by Dr. Falk Pharma GmbH).
  • an aerosol with fixed dose injection type for rectal injection of which the appearance and weight, and the like are indistinguishable from the test drug, and which does not contain budesonide, is used.
  • the subjects are ulcerative colitis patients in active phase, and are divided into a group administered the test drug once a day (hereinafter, once a day group, 54 cases), a group administered the test drug twice a day (hereafter, twice a day group, 55 cases), and a group administered the control drug (hereinafter, placebo group, 56 cases).
  • the test drug or control drug is rectally administered twice a day (once in the morning and once in the evening), after defecation, if possible. However, for the once a day group of test drug, a control drug is administered in the morning and a test drug is administered in the evening. The number of injections per dose is one, the administration period is 6 weeks, and the drug is administered until the evening before the evaluation.
  • the dose of budesonide in each group is 2 mg/day for the once a day group, 4 mg/day for the twice a day group, and 0 mg/day for the placebo group.
  • the point estimate of the odds ratio for the placebo group (95% confidence interval on both sides) in the logistic regression model with model as main effect model, remission rate as objective variable, and administration group and assignment factor as explanatory variables is 3.994 (1.734 to 9.711) in the once a day group, and 3.674 (1.594 to 8.930) in the twice a day group.
  • the lower limit value of 95% confidence interval on both sides exceeds 1 in both groups.
  • the remission rate in a case where 2 mg of budesonide is administered once a day for 6 weeks and in a case where 2 mg of budesonide is administered twice a day for 6 weeks is significantly higher than that in the placebo group, and the efficacy of this drug for patients with ulcerative colitis in active phase is confirmed.
  • the average value (95% confidence interval on both sides) of mucosal remission rates (endoscopic score ⁇ proportion of subjects with 1 point) (%) in each group is 46.3% (33.7% to 59.4%) in the placebo group, 69.1% (56.0% to 79.7%) in the once a day group, and 76.8% (64.2% to 85.9%) in the twice a day group.
  • the difference point estimate (95% confidence interval on both sides) from the placebo group is 22.8% (4.3% to 39.3%) in the once a day group, 30.5% (12.3% 46.0%) in the twice a day group.
  • Significant differences are observed in the once a day group and twice a day group as compared with the placebo group.
  • the results are illustrated in Table 1 and FIG. 1 .
  • “budesonide once a day administration group” illustrates the result of once a day group
  • “budesonide twice a day administration group” illustrates the result of twice a day group, respectively.
  • serum cortisol decrease and serum corticotropin decrease occurs as adverse events due to administration of the test drug. Although it is indicated that the incidence of adverse events increased in the twice a day group as compared with once a day group, increase in the incidence of adverse events related to glucocorticoids is not observed, and serious adverse events or severe adverse events are not occurred.
  • the dosing period of Application Example 1 is illustrated in Table 3.
  • the group administered twice a day is administered for 15 to 45 days, and the group administered for 42 days or more is 78.6%.
  • the administration schedule is ⁇ 3 days as conformity.
  • the enema for rectal application according to the present invention has remarkably high healing effect on intestinal mucosa where ulcer and erosion occur due to inflammation. Therefore, the enema for rectal application according to the present invention is extremely excellent as an enema for rectal application in order to treat the inflammatory bowel disease such as ulcerative colitis and Crohn's disease or the like, or to prevent a relapse.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
US15/546,476 2015-01-26 2015-07-21 Enema for rectal application Abandoned US20180271786A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015012723 2015-01-26
JP2015-012723 2015-01-26
PCT/JP2015/070667 WO2016121147A1 (ja) 2015-01-26 2015-07-21 注腸剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/070667 A-371-Of-International WO2016121147A1 (ja) 2015-01-26 2015-07-21 注腸剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/581,354 Continuation US20220142921A1 (en) 2015-01-26 2022-01-21 Enema for rectal application

Publications (1)

Publication Number Publication Date
US20180271786A1 true US20180271786A1 (en) 2018-09-27

Family

ID=56542786

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/546,476 Abandoned US20180271786A1 (en) 2015-01-26 2015-07-21 Enema for rectal application
US17/581,354 Pending US20220142921A1 (en) 2015-01-26 2022-01-21 Enema for rectal application

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/581,354 Pending US20220142921A1 (en) 2015-01-26 2022-01-21 Enema for rectal application

Country Status (10)

Country Link
US (2) US20180271786A1 (de)
EP (1) EP3251676A4 (de)
JP (3) JP6940279B2 (de)
CN (1) CN107249595A (de)
AU (1) AU2015379295A1 (de)
CA (1) CA2973542A1 (de)
EA (1) EA201791686A8 (de)
HK (1) HK1245102A1 (de)
IL (1) IL253603A0 (de)
WO (1) WO2016121147A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464733B2 (en) 2016-12-28 2022-10-11 Dr. Falk Pharma Gmbh Enema for rectal application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016121147A1 (ja) * 2015-01-26 2016-08-04 Ｅａファーマ株式会社 注腸剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140034998A1 (en) * 2012-07-03 2014-02-06 Infineon Technologies Ag Semiconductor Device with Laterally Varying Doping Concentrations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201505635A (zh) * 2013-05-21 2015-02-16 Salix Pharmaceuticals Inc 治療潰瘍性結腸炎之方法
WO2016121147A1 (ja) 2015-01-26 2016-08-04 Ｅａファーマ株式会社 注腸剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140034998A1 (en) * 2012-07-03 2014-02-06 Infineon Technologies Ag Semiconductor Device with Laterally Varying Doping Concentrations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464733B2 (en) 2016-12-28 2022-10-11 Dr. Falk Pharma Gmbh Enema for rectal application

Also Published As

Publication number Publication date
JP2022173567A (ja) 2022-11-18
JP7186735B2 (ja) 2022-12-09
JPWO2016121147A1 (ja) 2017-11-02
JP6940279B2 (ja) 2021-09-22
EA201791686A8 (ru) 2018-10-31
EP3251676A4 (de) 2018-09-19
CN107249595A (zh) 2017-10-13
EP3251676A1 (de) 2017-12-06
WO2016121147A1 (ja) 2016-08-04
HK1245102A1 (zh) 2018-08-24
CA2973542A1 (en) 2016-08-04
JP2020066636A (ja) 2020-04-30
EA201791686A1 (ru) 2018-04-30
AU2015379295A1 (en) 2017-08-10
US20220142921A1 (en) 2022-05-12
IL253603A0 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
US20220142921A1 (en) Enema for rectal application
EP0893998B2 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
KR102280700B1 (ko) Vegf 및 tgf 베타의 멀티키나제 저해제 및 이의 용도
US20140256661A1 (en) Pharmaceutical compositions for rectal administration
JP2017132791A (ja) 組み合わせ組成物
JP2019532112A (ja) 結節性痒疹の治療方法
JP2002537255A (ja) リウマチ性炎症性プロセスに対する５−ｈｔ３レセプターアンタゴニストの全身的使用
US11464733B2 (en) Enema for rectal application
ES2617235T3 (es) Uso de pidotimod para tratar psoriasis
KR101320945B1 (ko) 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
US8426392B2 (en) Method for providing emergency contraception
Rajaram Review of Captopril Drug Formulation, Mechanism of action, Dosage, Use and Adverse drug reactions
US20150352081A1 (en) Use of pidotimod to treat atopic dermatitis
RU2538433C1 (ru) Фармацевтическая композиция для профилактики и лечения инфекционно-воспалительных заболеваний различной этиологии путем оромукозного введения
US20150132284A1 (en) Method of treating ulcerative colitis
JP6935930B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
Sudarsa et al. A case of pemphigus vulgaris in a patient with abdominal tumor as collaborative disease
CN113827590A (zh) 右美托咪定在助眠药物制备中的应用
EA037259B1 (ru) Применение фармацевтической композиции с фиксированной дозой, содержащей мометазон и азеластин, для лечения аллергического ринита и способ лечения аллергического ринита
Seewoodhary et al. New treatments for erectile dysfunction
US9492546B2 (en) Use of bethanechol for treatment of Xerostomia
CN112438981A (zh) 羟基积雪草酸制备预防或治疗溃疡性结肠炎药物中的应用
JP2023120462A (ja) 医薬組成物
US20140349983A1 (en) Method for treating ulcerative colitis
BR102013000830A2 (pt) Composição farmacêutica para administração nasal, e, uso da mesma

Legal Events

Date Code Title Description
AS Assignment

Owner name: DR. FALK PHARMA GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EA PHARMA CO., LTD.;REEL/FRAME:044829/0771

Effective date: 20171225

Owner name: EA PHARMA CO., LTD., JAPAN

Free format text: CONFIRMATORY;ASSIGNOR:AJINOMOTO CO., INC.;REEL/FRAME:045245/0388

Effective date: 20171225

Owner name: AJINOMOTO CO., INC., JAPAN

Free format text: CONFIRMATORY;ASSIGNORS:YAMADA, YOJI;KONDO, SYOJI;KAJIOKA, TOSHIFUMI;REEL/FRAME:045248/0433

Effective date: 20180110

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION